Prescription weight loss medication has become a serious consideration for many Australians who struggle with obesity or weight-related health conditions. These treatments are tightly regulated, requiring medical oversight to ensure both safety and effectiveness.
With growing demand, more clinics across the country now provide access to medications that help regulate appetite, manage blood sugar, and support long-term weight management.
Comparison of Approved Weight Loss Medications in Australia
Australia has several prescription medications approved for long-term weight management, each working in different ways and carrying its own set of benefits and risks. The table below outlines the main options, including typical doses, how they work, common side effects, and how results compare against placebo groups in clinical trials.
Swipe to scroll the table below →
| Medication Name | Typical Doses | Mode of Action | Common Side Effects | Placebo Comparison |
|---|---|---|---|---|
| Semaglutide | Weekly injection (0.25 mg to 2.4 mg) | Mimics GLP-1 hormone to slow gastric emptying, reduce appetite, and improve blood sugar control | Nausea, vomiting, diarrhea, constipation, abdominal pain | Clinical trials show average weight reduction significantly higher than placebo, with placebo groups typically losing 2–3% body weight |
| Liraglutide | Daily injection (0.6 mg to 3.0 mg) | GLP-1 receptor agonist that decreases appetite and delays stomach emptying | Nausea, headache, diarrhea, fatigue | Studies report around 5–8% body weight loss compared to placebo averages of 2–3% |
| Orlistat | Oral capsule (120 mg up to 3 times daily with meals) | Blocks absorption of dietary fat in the intestines | Oily stools, flatulence, urgency, abdominal discomfort | Produces modest weight loss, usually 3–4% greater than placebo over a year |
| Phentermine (short-term use) | Oral tablet (15–30 mg daily, typically ≤12 weeks) | Suppresses appetite by stimulating the central nervous system | Insomnia, increased heart rate, dry mouth, nervousness | More effective than placebo short-term, though long-term use is not approved in Australia |
Semaglutide
Semaglutide is a once-weekly GLP-1 receptor agonist that reduces appetite and slows gastric emptying, helping people consume fewer calories and manage blood sugar more effectively.
It is administered as a subcutaneous injection, with doses typically ranging up to 2.4 mg for weight management. Clinical trials highlight its strong effect, making it one of the most widely studied medications in obesity care.
The STEP-1 trial found that participants taking semaglutide lost an average of 14.9% of their body weight over 68 weeks, compared with just 2.4% for the placebo group. The most common side effects were nausea, vomiting, and diarrhea, which tended to occur early in treatment.
In Australia, the Therapeutic Goods Administration (TGA) has registered semaglutide for chronic weight management under the brand Wegovy, confirming its availability within medical supervision.
At-a-Glance:
- Who it’s for: Adults with obesity or overweight with health risks.
- How it’s taken: Weekly injection up to 2.4 mg.
- Key watch-outs: Gastrointestinal side effects, requires medical supervision.
Liraglutide
Liraglutide is another GLP-1 receptor agonist, but unlike semaglutide, it requires daily injections instead of weekly dosing. It works by mimicking natural gut hormones that regulate appetite and satiety, leading to reduced calorie intake and gradual weight loss. The medication is typically prescribed at doses up to 3.0 mg for weight management purposes.
Evidence from the SCALE trial demonstrated its effectiveness, with 63.2% of participants losing at least 5% of body weight compared to 27.1% on placebo. Around one-third of participants achieved a 10% reduction in body weight, showing its potential for clinically significant results.
Common side effects included nausea, headache, and diarrhea, most of which were manageable with dose adjustments. In Australia, liraglutide 3.0 mg is approved by the TGA under the brand Saxenda.
At-a-Glance:
- Who it’s for: Adults with BMI over 30, or BMI over 27 with comorbidities.
- How it’s taken: Daily injection up to 3.0 mg.
- Key watch-outs: Digestive side effects, requires strict adherence to daily dosing.
Orlistat
Orlistat works differently from GLP-1 receptor agonists, as it does not affect appetite directly but instead blocks the absorption of dietary fat in the intestines. It is taken orally with meals, usually at a dose of 120 mg, and must be paired with a low-fat diet to reduce the intensity of gastrointestinal side effects. By reducing fat absorption, it lowers overall calorie intake and supports gradual weight loss.
The XENDOS study provided strong long-term evidence, showing that orlistat not only produced greater weight loss than placebo over four years but also reduced the risk of type 2 diabetes by 37%. However, side effects such as oily stools, flatulence, and an urgent need to use the bathroom were frequent and sometimes difficult for patients to tolerate.
In Australia, orlistat is registered under the brand Xenical and is prescribed for adults who meet BMI and health risk thresholds.
At-a-Glance:
- Who it’s for: Adults needing modest weight reduction with medical guidance.
- How it’s taken: Oral capsule, 120 mg with meals.
- Key watch-outs: Gastrointestinal discomfort, diet must be carefully managed.
Phentermine (short-term)
Phentermine is a stimulant that works by suppressing appetite through its action on the central nervous system. It is taken orally, usually at doses ranging from 15–40 mg daily, and is prescribed for no more than 12 weeks at a time. Doctors typically combine it with diet and exercise advice to maximize results while monitoring for safety.
Short-term clinical trials have shown that phentermine is more effective than placebo for rapid weight loss, with measurable reductions in body weight over weeks rather than months. However, it carries risks such as insomnia, nervousness, dry mouth, and an increased heart rate, which limit its use.
Rare but serious adverse events, such as pulmonary hypertension, have been noted historically. In Australia, phentermine is approved under the brand Duromine and is only available by prescription.
At-a-Glance:
- Who it’s for: Adults needing short-term medical weight loss support.
- How it’s taken: Oral tablet, 15–40 mg daily.
- Key watch-outs: Risk of stimulant-related side effects, limited to ≤12 weeks use.
Key Considerations Before Starting Treatment
Prescription weight loss medications are not general lifestyle products; they are medical therapies that come with responsibilities and risks. Anyone considering them in Australia needs to weigh medical oversight, potential side effects, and practical factors like cost and access.
Medical Oversight and Monitoring
All weight loss medications available in Australia require prescription by a licensed doctor, and follow-up is not optional. Regular check-ins allow physicians to adjust dosage, track side effects, and ensure the medication is working as intended. Without supervision, the risks of complications or misuse increase significantly.
Potential Side Effects
Every medication carries side effects, some mild and others serious. For GLP-1 receptor agonists like semaglutide and liraglutide, digestive issues such as nausea and diarrhea are most common, while orlistat often leads to oily stools and urgency. Phentermine can affect the nervous system, leading to insomnia or increased heart rate. Doctors weigh these risks against the expected benefits before prescribing.
Cost and Availability
Another factor is affordability and supply. GLP-1 medications like semaglutide and liraglutide can be expensive, and supply shortages have been reported globally, sometimes affecting access in Australia. Orlistat and phentermine are generally more affordable, but their effectiveness and limitations differ, making a doctor’s guidance on choice essential.
Meal Replacement in Weight Management
Meal replacement shakes are another option sometimes used in structured weight loss programs. They are clinically tested, highly controlled in energy content, and are only effective when used under professional guidance.
- Meal replacement shakes are intended for short-term use and differ from regular protein shakes.
- Clinical research confirms that very low energy meal replacements can help manage obesity when overseen by a doctor and dietitian.
- They may be used as a standalone therapy before transitioning to a balanced, portion-controlled eating plan.
- Because they are very low in carbohydrates, the body first uses stored glycogen for energy.
- After three to four days, once glycogen is depleted, the body shifts to burning stored fat, which drives weight loss.
The Future of Weight Loss Medication in Australia
The availability of prescription weight loss medication in Australia continues to evolve. Regulatory approvals, international demand, and new clinical trial results are shaping how these treatments will be prescribed and accessed in the years ahead.
Emerging Medications
Several new therapies are under review that may expand the options available beyond semaglutide, liraglutide, orlistat, and phentermine. Dual-acting drugs that target both GLP-1 and other pathways, such as GIP, have shown promising results in trials overseas. If approved by the TGA, these medications could offer stronger weight loss effects with different side effect profiles.
Supply and Access Challenges
Australia has already experienced shortages of GLP-1 medications due to global demand. Future supply will depend on production capacity and distribution agreements, which means availability could remain limited at times. This makes it important for patients to discuss alternative strategies with their doctors if a medication is temporarily unavailable.
Long-Term Care Models
The role of digital clinics and telehealth in prescribing weight loss medications is expected to expand. Programs are moving toward integrated care models that combine prescriptions with ongoing dietary advice, exercise guidance, and psychological support. These shifts aim to create long-term outcomes rather than short-term fixes.
Conclusion
Prescription weight loss medication in Australia has become a structured option for people who meet clinical criteria and require medical oversight. From GLP-1 receptor agonists like semaglutide and liraglutide to orlistat and short-term phentermine, each medicine has its own benefits, risks, and limitations. Meal replacement shakes can also play a role under professional supervision, showing that treatment pathways are diverse and adaptable.
Access to these medications depends on strict eligibility checks, careful monitoring, and the availability of supply.
The future may bring new therapies and broader telehealth integration, but the guiding principle remains the same: these treatments are medical tools, not quick fixes, and should always be used with professional guidance.